GlassScriptPhysician profile
Matthew Shaver
NPI 1376272815
$3,014.94
in general payments reported to CMS, 2019-2025
18 companies · $940 in 2025
The $940 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $288 · 2023: $920 · 2024: $866 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,726.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $698.45 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $424.93 | 2023-2025 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $424.34 | 2023-2025 | |
| Exact Sciences Corporation | $234.39 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $204.28 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $200.25 | 2022-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Antares Pharma, INC. | $164.65 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Janssen Pharmaceuticals, INC | $150.98 | 2023-2024 | Xarelto |
| Amgen INC. | $133.55 | 2024-2025 | Evenity, Prolia |
| Lilly USA, LLC | $90.99 | 2022-2024 | Mounjaro, Jardiance |
| Kowa Pharmaceuticals America, INC. | $71.09 | 2022-2023 | Livalo, Seglentis |
| Halozyme INC | $51.65 | 2023 | |
| Pfizer INC. | $37.42 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $36.23 | 2022-2023 | Eliquis |
| Almatica Pharma LLC | $31.51 | 2023 | Gralise, Loreev Xr, Sertraline Hcl |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $23.91 | 2023 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $20.04 | 2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $16.28 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Shaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.